摘要
目的探讨生脉注射液联合胸腺肽对乳腺癌化疗患者生活质量及化疗相关毒性反应的影响。方法将2010年10月至2015年10月该院收治的60例乳腺癌患者随机分为治疗组和对照组,各30例。两组患者均采用含有阿霉素的标准方案化疗,对照组采用单纯化疗,治疗组在化疗的同时加用生脉注射液和胸腺肽。比较分析两组患者治疗前后卡劳夫斯基功能状态评分(KPS评分),以及血常规、肝肾功能、心电图、T细胞亚群、自然杀伤(NK)细胞情况。结果经治疗后,治疗组的KPS评分、白细胞计数及血小板计数下降、心电图异常患者所占比例均低于对照组,T细胞亚群及NK细胞占比高于对照组,差异均有统计学意义(P<0.05)。两组患者均未出现明显肝、肾功能异常。结论生脉注射液联合胸腺肽注射液可以改善乳腺癌化疗患者的生活质量,降低骨髓抑制发生率,提高患者免疫功能,并能预防和减轻阿霉素所致心脏毒性。
Objective To investigate the influence of Shengmai Injection and thymosin on the living quality and chemotherapy related toxicity in chemotherapeutic patients with breast cancer. Methods Sixty cases of breast cancer in our hos-pital from October 2010 to October 2015 were randomly divided into the treatment group and control group ,30 cases in each group. The two groups adopted the standard chemotherapy containing adriamycin. The control group adopted the simple chemotherapy , while the treatment group was added with Shengmai Injection and thymosin at the same time of chemotherapy. The KPS scores , blood routine index,hepatorenal function,electrocardiogram,T lymphocyte subsets and NK cells before and after therapy were comparatively analyzed in the two groups. Results The proportions of patients with descending KPS score,WBC count,platelet count,and EKG abnormal after treatment in the treatment group were lower than those in the control group ,while the proportion of T lymphocyte subsets and NK cell were higher than those in the control group,the differences were statistically significant（P〈0.05）. No obvious hepatorenal function abnormality appeared. Conclusion Shengmai Injection combined with thymosin could improve the living quality in chemotherapeutic patients with breast cancer ,reduces the myelosuppression occurrence rate ,increases the immunity function,and prevents and lightens the adriamycin caused cardiac toxicity.
出处
《现代医药卫生》
2016年第15期2312-2314,共3页
Journal of Modern Medicine & Health
关键词
生脉散
注射剂
胸腺素
乳腺肿瘤
药物疗法
联合
生活质量
Shengmai powders
Injection
Thymosin
Breast neoplasms
Drug therapy,combination
Quality of life
